5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy

5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy a new study published in Arthritis Research & Therapy examines the use of 5-LOXIN®, with researchers observing clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Turmeric supplements show promise in treating arthritis New study published in the November 2006 issue of Arthritis & Rheumatism examines the effect and mechanism of turmeric on arthritis, shows that a version free of essential oils prevented acute and chronic arthritis, even when it was administered after arthritis had been induced, as well as inhibited a protein that controls the gene expression of substances that produce an inflammatory response. New In-Vitro Study Finds Hyal-Joint(TM) Nourishes Synovial Fluid During the study, a culture of human osteoarthritic synoviocytes were stimulated using either Hyal-Joint(TM), with researchers observing that after the 12 and 24 hour¹ incubation periods, the cell culture stimulated using Hyal-Joint(TM) demonstrated significantly higher values of endogenous HA than the cell culture stimulated by HA from bacterial fermentation. New In-Vitro Study Finds Hyal-Joint(TM) Nourishes Synovial Fluid During the study, a culture of human osteoarthritic synoviocytes were stimulated using either Hyal-Joint(TM), with researchers observing that after the 12 and 24 hour¹ incubation periods, the cell culture stimulated using Hyal-Joint(TM) demonstrated significantly higher values of endogenous HA than the cell culture stimulated by HA from bacterial fermentation. New In-Vitro Study Finds Hyal-Joint(TM) Nourishes Synovial Fluid During the study, a culture of human osteoarthritic synoviocytes were stimulated using either Hyal-Joint(TM), with researchers observing that after the 12 and 24 hour¹ incubation periods, the cell culture stimulated using Hyal-Joint(TM) demonstrated significantly higher values of endogenous HA than the cell culture stimulated by HA from bacterial fermentation. WOKVEL® Extract found effective in comparative human study for joint health Study, published in the February 2007 issue of the Indian Journal of Pharmacology found a sustained decrease in WOMAC score for WOKVEL Extract and valdecoxib, a non-steroidal anti-inflammatory drug (NSAID) over a seven month period. WOKVEL® Extract found effective in comparative human study for joint health Study, published in the February 2007 issue of the Indian Journal of Pharmacology found a sustained decrease in WOMAC score for WOKVEL Extract and valdecoxib, a non-steroidal anti-inflammatory drug (NSAID) over a seven month period. WOKVEL® Extract found effective in comparative human study for joint health Study, published in the February 2007 issue of the Indian Journal of Pharmacology found a sustained decrease in WOMAC score for WOKVEL Extract and valdecoxib, a non-steroidal anti-inflammatory drug (NSAID) over a seven month period. New Study Finds Celadrin® Significantly Improves Knee Function and Joint Mobility Research study conducted with Celadrin® shows that after eight weeks of capsule consumption, average walking ability increased 45 percent, and participants claimed a 35 percent decrease in knee discomfort. New Study Finds Celadrin® Significantly Improves Knee Function and Joint Mobility Research study conducted with Celadrin® shows that after eight weeks of capsule consumption, average walking ability increased 45 percent, and participants claimed a 35 percent decrease in knee discomfort. New Study Finds Celadrin® Significantly Improves Knee Function and Joint Mobility Research study conducted with Celadrin® shows that after eight weeks of capsule consumption, average walking ability increased 45 percent, and participants claimed a 35 percent decrease in knee discomfort. Study confirms “MSM provides moderate evidence of efficacy for knee OA” The journal Arthritis Research & Therapy reviewed 2,026 OA nutritional supplement studies and concludes that only three supplements including MSM are supported by good to moderate evidence. Study confirms “MSM provides moderate evidence of efficacy for knee OA” The journal Arthritis Research & Therapy reviewed 2,026 OA nutritional supplement studies and concludes that only three supplements including MSM are supported by good to moderate evidence. Study confirms “MSM provides moderate evidence of efficacy for knee OA” The journal Arthritis Research & Therapy reviewed 2,026 OA nutritional supplement studies and concludes that only three supplements including MSM are supported by good to moderate evidence. INTER FARMA's response to the "Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip" Ibter-Farma and Dr. Jose N. Racca MD, MSc, PhD comment on the april 17, 2007 Annals of Internal Medicine article. (Volume 146, Issue 8, Pages 580 to 590.) INTER FARMA's response to the "Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip" Ibter-Farma and Dr. Jose N. Racca MD, MSc, PhD comment on the april 17, 2007 Annals of Internal Medicine article. (Volume 146, Issue 8, Pages 580 to 590.) INTER FARMA's response to the "Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip" Ibter-Farma and Dr. Jose N. Racca MD, MSc, PhD comment on the april 17, 2007 Annals of Internal Medicine article. (Volume 146, Issue 8, Pages 580 to 590.) INTER FARMA's response to the "Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip" Ibter-Farma and Dr. Jose N. Racca MD, MSc, PhD comment on the april 17, 2007 Annals of Internal Medicine article. (Volume 146, Issue 8, Pages 580 to 590.) HHS: Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee A new scientific review released today by the Department of Health & Human Services's (HHS) Agency for Healthcare Research and Quality (AHRQ) concludes that evidence of benefit is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary supplement ingredients. HHS: Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee A new scientific review released today by the Department of Health & Human Services's (HHS) Agency for Healthcare Research and Quality (AHRQ) concludes that evidence of benefit is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary supplement ingredients. HHS: Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee A new scientific review released today by the Department of Health & Human Services's (HHS) Agency for Healthcare Research and Quality (AHRQ) concludes that evidence of benefit is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary supplement ingredients. Advances In the Treatment Of Synovitis New information and additional research will be the subject of an educational symposium following the Annual Scientific Meeting of the American College of Rheumatology (ACR). The half-day symposium entitled “Osteoarthritis and Synovitis: The Link Between Pathogenesis, Detection and Treatment,” will be held Sunday, November 11, 2007 at the Westin Boston Waterfront Hotel in Boston, MA. Advances In the Treatment Of Synovitis New information and additional research will be the subject of an educational symposium following the Annual Scientific Meeting of the American College of Rheumatology (ACR). The half-day symposium entitled “Osteoarthritis and Synovitis: The Link Between Pathogenesis, Detection and Treatment,” will be held Sunday, November 11, 2007 at the Westin Boston Waterfront Hotel in Boston, MA. Advances In the Treatment Of Synovitis New information and additional research will be the subject of an educational symposium following the Annual Scientific Meeting of the American College of Rheumatology (ACR). The half-day symposium entitled “Osteoarthritis and Synovitis: The Link Between Pathogenesis, Detection and Treatment,” will be held Sunday, November 11, 2007 at the Westin Boston Waterfront Hotel in Boston, MA. Study Shows Pine Bark Improved Physical Function A double-blind, placebo-controlled study published in the journal Nutrition Research reveals Pycnogenol(R), an antioxidant plant extract from the bark of the French maritime pine tree, improved physical function by 52 percent in patients suffering from OA. Study Shows Pine Bark Improved Physical Function A double-blind, placebo-controlled study published in the journal Nutrition Research reveals Pycnogenol(R), an antioxidant plant extract from the bark of the French maritime pine tree, improved physical function by 52 percent in patients suffering from OA. Study Shows Pine Bark Improved Physical Function A double-blind, placebo-controlled study published in the journal Nutrition Research reveals Pycnogenol(R), an antioxidant plant extract from the bark of the French maritime pine tree, improved physical function by 52 percent in patients suffering from OA. Findings Presented at the OsteoArthritis Research Society Researchers from the University of California, San Diego presented new research findings yesterday at the 2007 World Congress on Osteoarthritis in Ft. Lauderdale, providing the first evidence of how methylsulfonylmethane (MSM) may protect articular cartilage and reduce inflammation in osteoarthritis. The form of MSM used in the study, OptiMSM was provided by Bergstrom Nutrition. Findings Presented at the OsteoArthritis Research Society Researchers from the University of California, San Diego presented new research findings yesterday at the 2007 World Congress on Osteoarthritis in Ft. Lauderdale, providing the first evidence of how methylsulfonylmethane (MSM) may protect articular cartilage and reduce inflammation in osteoarthritis. The form of MSM used in the study, OptiMSM was provided by Bergstrom Nutrition. Findings Presented at the OsteoArthritis Research Society Researchers from the University of California, San Diego presented new research findings yesterday at the 2007 World Congress on Osteoarthritis in Ft. Lauderdale, providing the first evidence of how methylsulfonylmethane (MSM) may protect articular cartilage and reduce inflammation in osteoarthritis. The form of MSM used in the study, OptiMSM was provided by Bergstrom Nutrition. Second University Study Shows OptiMSM(TM) Slows Development of Osteoarthritis A new study presented at the Experimental Biology 2008 Annual Meeting, by researchers from the University of California, San Diego, has revealed a protective effect of OptiMSM upon the development of osteoarthritis of the knee in an animal model. Second University Study Shows OptiMSM(TM) Slows Development of Osteoarthritis A new study presented at the Experimental Biology 2008 Annual Meeting, by researchers from the University of California, San Diego, has revealed a protective effect of OptiMSM upon the development of osteoarthritis of the knee in an animal model. Second University Study Shows OptiMSM(TM) Slows Development of Osteoarthritis A new study presented at the Experimental Biology 2008 Annual Meeting, by researchers from the University of California, San Diego, has revealed a protective effect of OptiMSM upon the development of osteoarthritis of the knee in an animal model. Study Indicates Pine Bark Naturally Reduces Osteoarthritis Symptoms a study to be published in the journal of Phytotherapy Research shows Pycnogenol(R) was shown to reduce all osteoarthritis symptoms by 56 percent. Study Indicates Pine Bark Naturally Reduces Osteoarthritis Symptoms a study to be published in the journal of Phytotherapy Research shows Pycnogenol(R) was shown to reduce all osteoarthritis symptoms by 56 percent. Study Indicates Pine Bark Naturally Reduces Osteoarthritis Symptoms a study to be published in the journal of Phytotherapy Research shows Pycnogenol(R) was shown to reduce all osteoarthritis symptoms by 56 percent. Hyabest® (J) - Recent Research supports efficacy for Knee Osteoarthritis Q.P. Corporation has developed an innovative hyaluronic acid specially designed for those with knee osteoarthritis - HyabestⓇ(J). For this product, they recently obtained 8-week clinical data based on a WOMAC randomized double-blind placebo-controlled clinical trial, which followed a successful result obtained earlier from a similar trial in Japan (JKOM). Hyabest® (J) - Recent Research supports efficacy for Knee Osteoarthritis Q.P. Corporation has developed an innovative hyaluronic acid specially designed for those with knee osteoarthritis - HyabestⓇ(J). For this product, they recently obtained 8-week clinical data based on a WOMAC randomized double-blind placebo-controlled clinical trial, which followed a successful result obtained earlier from a similar trial in Japan (JKOM). Hyabest® (J) - Recent Research supports efficacy for Knee Osteoarthritis Q.P. Corporation has developed an innovative hyaluronic acid specially designed for those with knee osteoarthritis - HyabestⓇ(J). For this product, they recently obtained 8-week clinical data based on a WOMAC randomized double-blind placebo-controlled clinical trial, which followed a successful result obtained earlier from a similar trial in Japan (JKOM). Hyabest® (J) - Recent Research supports efficacy for Knee Osteoarthritis Q.P. Corporation has developed an innovative hyaluronic acid specially designed for those with knee osteoarthritis - HyabestⓇ(J). For this product, they recently obtained 8-week clinical data based on a WOMAC randomized double-blind placebo-controlled clinical trial, which followed a successful result obtained earlier from a similar trial in Japan (JKOM). Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. Gelita Announces Latest Osteoarthritis Research Findings GELITA has announced the results of two clinical trials regarding their Fortigel product. The research was conducted by Harvard Medical School and Tufts Medical Center, and the Kiel-based Collagen Research Institute of Kiel University. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. ESM Technologies Presenting on Joint and Bone Health Ingredients in Las Vegas ESM Technologies has announced they will be presenting "Joint Health in Record Time: Clinically Effective Results from NEM(R) in 10 days," in Las Vegas, Friday, November 13, at 2:30 pm. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	MORRISTOWN, NJ (1 August 2008) ..... PL Thomas (PLT), in alliance with Laila Nutraceuticals, India, today jointly announced the publication of a new study using their exclusive dietary supplement ingredient, 5-LOXIN®. In the study, 5-LOXIN supplementation conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients at doses of 100mg and 250mg daily. Interestingly, significant improvements in pain score and functional ability were recorded in as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, a significant reduction in synovial fluid MMP activity, enzymes which damage connective tissue, was noted. 5-LOXIN was found to be well-tolerated, with no safety concerns. Arthritis Research & Therapy 2008, 10:R85doi:10.1186/ar2461 click here The study was led by Siba Raychaudhuri, a faculty member of the University of California, Davis, in the United States. According to an interview with the journal, Dr. Raychaudhuri said, "The high incidence of adverse affects associated with currently available medications has created great interest in the search for an effective and safe alternative treatment." The ingredient used by the authors was 5-LOXIN, (a unique, patent pending extract of Boswellia seratta) providing 30% AKBA (3-O-acetyl-11-keto-beta-boswellic acid). Raychaudhuri continued, "AKBA has anti-inflammatory properties, and we have shown that a Boswellia serrata extract with concentrated AKBA can be an effective treatment for osteoarthritis of the knee". Seventy-five OA patients were included in the study. Dived into three groups of 25, the patients were given daily either 100 mg 5-LOXIN, 250 mg 5-LOXIN or a placebo for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (VAS - visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid of the knee from OA patients. According to the authors, "In this study, the compound was shown to have no major adverse effects in our osteoarthritis patients. It is safe for human consumption and even for long-term use." 5-LOXIN is available in North America in Osteo Bi-Flex products with the Joint Shield blend sold in food, drug and mass market and club stores. For more information on this study please contact PL Thomas: phone: 973-984-0900, fax: 973-984-5666, e-mail: plt@plthomas.com or www.plthomas.com About Laila Nutraceuticals (LN) LN is a division of Laila Group, the largest producer of herbal extracts in India. LN works with Laila Impex Research Center to develop, manufacture and commercialize standardized herbal extracts & phytochemicals worldwide, and supports this work with patents and publications. About PLT PL Thomas & Co., a New Jersey-based ingredient supplier, offers fifty years of innovation in providing high quality ingredients for the food/functional food and nutrition industries. PLT successfully champions nutritional products and technologies "Where Food & Health Meet."
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software